Ionis Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 26 analysts polled by S&P Global, Ionis Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $100.92. The average 1-year stock price forecast is 37.73% higher than the current stock price, while the lowest is $47 (-35.86%) and the highest is $130 (+77.41%).

Price Target: $100.92 (+37.73%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$47	$100.92	$105	$130
Change	-35.86%	+37.73%	+43.30%	+77.41%

Analyst Ratings

The average analyst rating for Ionis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	10	10	10	11	12	12
Buy	6	6	6	8	9	9
Hold	6	6	6	5	5	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	22	22	22	24	26	26

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gary Nachman Canaccord Genuity	Canaccord Genuity	Buy Maintains $110	Buy	Maintains	$110	+50.12%	Jun 5, 2026
Unknown Analyst Guggenheim No rating	Guggenheim	Buy Maintains $106	Buy	Maintains	$106	+44.66%	Jun 5, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $125	Buy	Reiterates	$125	+70.59%	Jun 1, 2026
Michael Ulz Morgan Stanley	Morgan Stanley	Buy Reiterates $130	Buy	Reiterates	$130	+77.41%	May 29, 2026
Myles Minter William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	May 28, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

890.27M

from 943.71M

-5.66%

from 943.71M

Revenue Next Year

1.48B

from 890.27M

66.76%

from 890.27M

EPS This Year

-2.56

from -1.54

EPS Next Year

-0.62

from -2.56

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	810.46M	587.37M	787.65M	705.14M	943.71M	890.27M
Revenue Growth	11.13%	-27.53%	34.10%	-10.48%	33.83%	-5.66%
Gross Profit	156.16M	-259.90M	-121.11M	-207.61M	12.18M	856.44M
Gross Margin	19.27%	-44.25%	-15.38%	-29.44%	1.29%	96.20%
Operating Income	-30.19M	-410.19M	-353.73M	-475.08M	-381.68M	-615.09M
Net Income	-28.60M	-269.72M	-366.29M	-453.90M	-381.39M	-594.67M
EPS	-	-	-	-	-1.54	-2.56
Free Cash Flow	76.54M	-80.22M	-173.51M	-352.83M	-154.72M	-684.76M
No. Analysts	-	-	-	-	-	23

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	947.0M
Avg	890.3M
Low	833.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	0.3%
Avg	-5.7%
Low	-11.7%

EPS Forecast

EPS	2026	2027	2028
High	-2.04
Avg	-2.56
Low	-2.79

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-